| 101.695 -0.765 (-0.75%) | 07-31 14:06 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 122.63 | 1-year : | 143.24 |
| Resists | First : | 105 | Second : | 122.63 |
| Pivot price | 101.2  |
|||
| Supports | First : | 99.41 |
Second : | 95.95 |
| MAs | MA(5) : | 102.88 |
MA(20) : | 101.34 |
| MA(100) : | 91.66 |
MA(250) : | 83.9 |
|
| MACD | MACD : | 1.6 |
Signal : | 1.8 |
| %K %D | K(14,3) : | 62.7 |
D(3) : | 73 |
| RSI | RSI(14): 56.1 |
|||
| 52-week | High : | 105 | Low : | 63.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IHE ] has closed below upper band by 43.7%. Bollinger Bands are 0.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 102.93 - 103.49 | 103.49 - 103.95 |
| Low: | 100.32 - 101.04 | 101.04 - 101.63 |
| Close: | 101.38 - 102.47 | 102.47 - 103.38 |
The iShares U.S. Pharmaceuticals ETF is designed to replicate the investment performance of a benchmark index. This index consists solely of equity securities from pharmaceutical companies operating within the United States.
Fri, 31 Jul 2026
XLV vs. IHE: Which Healthcare ETF Is the Better Buy? - fool.com
Thu, 30 Jul 2026
How Ishares U.s. Pharmaceuticals Etf (IHE) Affects Rotational Strategy Timing - Stock Traders Daily
Thu, 30 Jul 2026
Will Generic Drug Tariffs Impact Pharma ETFs? - tradingview.com
Thu, 23 Jul 2026
ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook - tradingview.com
Wed, 22 Jul 2026
Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF? - The Globe and Mail
Wed, 22 Jul 2026
Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF? - fool.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|